Herminia Diana Rosas, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Huntington Disease | 47 | 2023 | 1111 | 7.390 |
Why?
|
| Nerve Fibers, Myelinated | 8 | 2018 | 960 | 1.280 |
Why?
|
| Down Syndrome | 9 | 2023 | 880 | 1.020 |
Why?
|
| Brain | 29 | 2022 | 26343 | 0.840 |
Why?
|
| Putamen | 2 | 2020 | 291 | 0.840 |
Why?
|
| Creatine | 4 | 2017 | 421 | 0.830 |
Why?
|
| Nerve Degeneration | 5 | 2018 | 748 | 0.820 |
Why?
|
| Cerebral Cortex | 11 | 2023 | 5705 | 0.770 |
Why?
|
| Myelin Sheath | 2 | 2018 | 652 | 0.730 |
Why?
|
| Parahippocampal Gyrus | 3 | 2016 | 116 | 0.730 |
Why?
|
| Alzheimer Disease | 15 | 2023 | 7988 | 0.720 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 8 | 2018 | 2736 | 0.580 |
Why?
|
| Trinucleotide Repeats | 7 | 2012 | 261 | 0.570 |
Why?
|
| Neostriatum | 1 | 2016 | 250 | 0.520 |
Why?
|
| Magnetic Resonance Imaging | 23 | 2020 | 35342 | 0.460 |
Why?
|
| Atrophy | 11 | 2014 | 1576 | 0.460 |
Why?
|
| Pattern Recognition, Visual | 1 | 2019 | 823 | 0.440 |
Why?
|
| Visual Pathways | 1 | 2016 | 565 | 0.410 |
Why?
|
| Neuroprotective Agents | 3 | 2017 | 941 | 0.390 |
Why?
|
| Visual Cortex | 3 | 2016 | 1149 | 0.370 |
Why?
|
| Axons | 2 | 2018 | 1681 | 0.370 |
Why?
|
| Hippocampus | 4 | 2016 | 3661 | 0.330 |
Why?
|
| Cognition Disorders | 6 | 2014 | 4030 | 0.330 |
Why?
|
| Corpus Callosum | 4 | 2009 | 737 | 0.320 |
Why?
|
| Diffusion Tensor Imaging | 9 | 2018 | 2304 | 0.320 |
Why?
|
| Limbic System | 1 | 2010 | 426 | 0.310 |
Why?
|
| Cerebrovascular Circulation | 3 | 2013 | 2732 | 0.300 |
Why?
|
| Aging | 8 | 2016 | 8626 | 0.290 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 2012 | 374 | 0.280 |
Why?
|
| Neural Pathways | 5 | 2015 | 2971 | 0.280 |
Why?
|
| Deoxyguanosine | 1 | 2006 | 84 | 0.270 |
Why?
|
| Amyloid beta-Peptides | 7 | 2023 | 3574 | 0.270 |
Why?
|
| Middle Aged | 50 | 2023 | 213127 | 0.250 |
Why?
|
| Fluorescence Resonance Energy Transfer | 3 | 2013 | 401 | 0.250 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 1440 | 0.250 |
Why?
|
| Neurologic Examination | 3 | 2009 | 931 | 0.250 |
Why?
|
| Cerebrovascular Disorders | 2 | 2022 | 1499 | 0.240 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2016 | 8925 | 0.240 |
Why?
|
| Iron | 1 | 2012 | 1773 | 0.230 |
Why?
|
| Brain Mapping | 9 | 2019 | 6669 | 0.230 |
Why?
|
| Adult | 48 | 2023 | 213712 | 0.230 |
Why?
|
| Female | 60 | 2023 | 379592 | 0.220 |
Why?
|
| Trinucleotide Repeat Expansion | 4 | 2013 | 242 | 0.220 |
Why?
|
| Temporal Lobe | 1 | 2010 | 1669 | 0.220 |
Why?
|
| Male | 58 | 2022 | 349538 | 0.220 |
Why?
|
| Positron-Emission Tomography | 7 | 2023 | 6259 | 0.220 |
Why?
|
| Disease Progression | 10 | 2018 | 13256 | 0.210 |
Why?
|
| Humans | 84 | 2023 | 742088 | 0.200 |
Why?
|
| tau Proteins | 5 | 2023 | 1860 | 0.200 |
Why?
|
| Observation | 2 | 2013 | 312 | 0.190 |
Why?
|
| Amyloid | 2 | 2020 | 795 | 0.190 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2020 | 3328 | 0.190 |
Why?
|
| Corpus Striatum | 3 | 2005 | 1220 | 0.180 |
Why?
|
| Choice Behavior | 1 | 2005 | 802 | 0.170 |
Why?
|
| Age of Onset | 8 | 2013 | 3266 | 0.170 |
Why?
|
| Infarction | 1 | 2020 | 243 | 0.170 |
Why?
|
| Riluzole | 1 | 1999 | 55 | 0.170 |
Why?
|
| Facial Expression | 1 | 2023 | 508 | 0.170 |
Why?
|
| Reaction Time | 1 | 2005 | 2092 | 0.160 |
Why?
|
| Nerve Tissue Proteins | 6 | 2013 | 4465 | 0.160 |
Why?
|
| Hypertrophy | 1 | 2020 | 568 | 0.160 |
Why?
|
| Mutant Proteins | 2 | 2010 | 500 | 0.160 |
Why?
|
| Thalamic Nuclei | 1 | 2018 | 114 | 0.150 |
Why?
|
| Neuropsychological Tests | 7 | 2016 | 6974 | 0.150 |
Why?
|
| Single-Blind Method | 2 | 2018 | 1589 | 0.150 |
Why?
|
| Anisotropy | 4 | 2010 | 1265 | 0.150 |
Why?
|
| Rotation | 1 | 2019 | 523 | 0.150 |
Why?
|
| Globus Pallidus | 1 | 2018 | 253 | 0.150 |
Why?
|
| Carbon Radioisotopes | 1 | 2018 | 592 | 0.140 |
Why?
|
| Neurodegenerative Diseases | 3 | 2022 | 1060 | 0.140 |
Why?
|
| Aged | 30 | 2023 | 162944 | 0.140 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 1999 | 449 | 0.140 |
Why?
|
| Acetamides | 1 | 2018 | 249 | 0.140 |
Why?
|
| Receptors, GABA | 1 | 2018 | 288 | 0.140 |
Why?
|
| Organ Size | 3 | 2010 | 2253 | 0.140 |
Why?
|
| Form Perception | 1 | 2016 | 182 | 0.130 |
Why?
|
| Ubiquinone | 1 | 2016 | 188 | 0.130 |
Why?
|
| Case-Control Studies | 9 | 2018 | 21719 | 0.130 |
Why?
|
| Attention | 1 | 2005 | 2396 | 0.130 |
Why?
|
| Motion Perception | 1 | 2019 | 408 | 0.120 |
Why?
|
| Double-Blind Method | 7 | 2017 | 12017 | 0.120 |
Why?
|
| rho-Associated Kinases | 1 | 2015 | 279 | 0.120 |
Why?
|
| Cross-Sectional Studies | 9 | 2023 | 24913 | 0.110 |
Why?
|
| Electrochemistry | 1 | 2013 | 145 | 0.110 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 15530 | 0.110 |
Why?
|
| Receptors, Kainic Acid | 1 | 2012 | 88 | 0.110 |
Why?
|
| Receptors, Dopamine | 1 | 2013 | 294 | 0.110 |
Why?
|
| Codon, Terminator | 1 | 2012 | 127 | 0.100 |
Why?
|
| Polymorphism, Genetic | 3 | 2013 | 4328 | 0.100 |
Why?
|
| Radiography, Abdominal | 1 | 2015 | 537 | 0.100 |
Why?
|
| Guanine | 1 | 2013 | 274 | 0.100 |
Why?
|
| Frontal Lobe | 4 | 2015 | 1407 | 0.100 |
Why?
|
| Reproducibility of Results | 5 | 2015 | 19862 | 0.100 |
Why?
|
| Emotions | 1 | 2023 | 2657 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2021 | 5095 | 0.100 |
Why?
|
| Psychomotor Performance | 3 | 2010 | 1895 | 0.090 |
Why?
|
| Creatine Kinase, BB Form | 1 | 2010 | 7 | 0.090 |
Why?
|
| Nuclear Proteins | 4 | 2010 | 5851 | 0.090 |
Why?
|
| Disease | 1 | 2016 | 681 | 0.090 |
Why?
|
| Astrocytes | 1 | 2018 | 1266 | 0.090 |
Why?
|
| Young Adult | 10 | 2020 | 56350 | 0.090 |
Why?
|
| Face | 1 | 2016 | 993 | 0.090 |
Why?
|
| Basal Ganglia | 2 | 2006 | 545 | 0.090 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 238 | 0.090 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 2030 | 0.090 |
Why?
|
| Microglia | 1 | 2018 | 1261 | 0.090 |
Why?
|
| Nerve Fibers, Unmyelinated | 1 | 2010 | 99 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2016 | 4029 | 0.080 |
Why?
|
| Entorhinal Cortex | 1 | 2010 | 264 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2013 | 1574 | 0.080 |
Why?
|
| Longitudinal Studies | 6 | 2021 | 13921 | 0.080 |
Why?
|
| Postmortem Changes | 3 | 2015 | 125 | 0.080 |
Why?
|
| Leukocytes | 2 | 2015 | 2039 | 0.080 |
Why?
|
| Internal Capsule | 2 | 2006 | 113 | 0.080 |
Why?
|
| Amygdala | 1 | 2016 | 1305 | 0.080 |
Why?
|
| Neurofilament Proteins | 2 | 2021 | 318 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2020 | 3461 | 0.080 |
Why?
|
| Parkinson Disease | 1 | 2022 | 2774 | 0.080 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 822 | 0.080 |
Why?
|
| Vitamins | 1 | 2016 | 1608 | 0.080 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 2658 | 0.080 |
Why?
|
| Thymidine | 1 | 1988 | 309 | 0.080 |
Why?
|
| Aged, 80 and over | 12 | 2016 | 57683 | 0.080 |
Why?
|
| Visual Perception | 1 | 2016 | 1417 | 0.080 |
Why?
|
| Time Factors | 4 | 2018 | 40054 | 0.080 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2013 | 895 | 0.080 |
Why?
|
| Retroviridae Infections | 1 | 1988 | 151 | 0.080 |
Why?
|
| Blood Flow Velocity | 1 | 2011 | 1423 | 0.080 |
Why?
|
| Extrapyramidal Tracts | 1 | 2006 | 18 | 0.070 |
Why?
|
| Sleep | 1 | 2023 | 4604 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 1835 | 0.070 |
Why?
|
| Valine | 1 | 2008 | 413 | 0.070 |
Why?
|
| Apolipoproteins E | 2 | 2023 | 1438 | 0.070 |
Why?
|
| Rett Syndrome | 1 | 2008 | 165 | 0.070 |
Why?
|
| Pyridines | 1 | 2018 | 2818 | 0.070 |
Why?
|
| Memory Disorders | 2 | 2004 | 1183 | 0.070 |
Why?
|
| Lumbar Vertebrae | 1 | 2015 | 1844 | 0.070 |
Why?
|
| Mice, Transgenic | 5 | 2023 | 9735 | 0.070 |
Why?
|
| Mice, Inbred CBA | 3 | 2011 | 447 | 0.070 |
Why?
|
| Methionine | 1 | 2008 | 590 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2015 | 1581 | 0.070 |
Why?
|
| Genetic Counseling | 1 | 2009 | 600 | 0.060 |
Why?
|
| Hand | 1 | 2010 | 882 | 0.060 |
Why?
|
| Biological Availability | 1 | 2006 | 396 | 0.060 |
Why?
|
| Early Diagnosis | 2 | 2009 | 1184 | 0.060 |
Why?
|
| Encephalitis | 2 | 2021 | 423 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2011 | 2372 | 0.060 |
Why?
|
| Dementia | 3 | 2008 | 2501 | 0.060 |
Why?
|
| Pyramidal Tracts | 1 | 2006 | 257 | 0.060 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2008 | 604 | 0.060 |
Why?
|
| Interferon Type I | 1 | 1988 | 542 | 0.060 |
Why?
|
| Insulin Resistance | 2 | 2016 | 3861 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2014 | 5062 | 0.060 |
Why?
|
| Prefrontal Cortex | 2 | 2023 | 2146 | 0.060 |
Why?
|
| Australia | 2 | 2017 | 1167 | 0.060 |
Why?
|
| Quality of Life | 2 | 2023 | 12730 | 0.060 |
Why?
|
| Lactic Acid | 2 | 1999 | 1132 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2012 | 15494 | 0.060 |
Why?
|
| Models, Neurological | 2 | 2008 | 1771 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2010 | 1354 | 0.050 |
Why?
|
| Antibodies | 1 | 2010 | 2459 | 0.050 |
Why?
|
| Genotype | 3 | 2021 | 12946 | 0.050 |
Why?
|
| Telomere | 1 | 2008 | 909 | 0.050 |
Why?
|
| Parietal Lobe | 1 | 2006 | 837 | 0.050 |
Why?
|
| Histones | 1 | 2011 | 2597 | 0.050 |
Why?
|
| Gliosis | 1 | 2021 | 243 | 0.050 |
Why?
|
| Motor Activity | 1 | 2010 | 2714 | 0.050 |
Why?
|
| Cohort Studies | 4 | 2018 | 40450 | 0.050 |
Why?
|
| Alleles | 4 | 2012 | 6931 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 1999 | 3760 | 0.040 |
Why?
|
| Predictive Value of Tests | 4 | 2009 | 15056 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 14720 | 0.040 |
Why?
|
| Serine | 1 | 2023 | 828 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2005 | 2633 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2013 | 4282 | 0.040 |
Why?
|
| Chorea | 1 | 1999 | 74 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2009 | 2585 | 0.040 |
Why?
|
| Nervous System Diseases | 3 | 2013 | 1617 | 0.040 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2006 | 855 | 0.040 |
Why?
|
| Functional Laterality | 1 | 2005 | 2290 | 0.040 |
Why?
|
| Inflammation | 1 | 2018 | 10578 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2005 | 2713 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2010 | 3584 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 1988 | 6608 | 0.040 |
Why?
|
| Family | 1 | 2009 | 3144 | 0.040 |
Why?
|
| Algorithms | 3 | 2015 | 13853 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2017 | 62966 | 0.040 |
Why?
|
| Occipital Lobe | 1 | 1999 | 380 | 0.040 |
Why?
|
| New Zealand | 1 | 2017 | 357 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 4187 | 0.040 |
Why?
|
| Genetic Testing | 2 | 2009 | 3439 | 0.040 |
Why?
|
| Encephalocele | 1 | 1997 | 135 | 0.030 |
Why?
|
| Lead Poisoning | 1 | 1998 | 304 | 0.030 |
Why?
|
| Dominance, Cerebral | 1 | 1997 | 635 | 0.030 |
Why?
|
| Staphylococcal Protein A | 1 | 1995 | 40 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 1988 | 2978 | 0.030 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2015 | 43 | 0.030 |
Why?
|
| Seizures | 1 | 2008 | 2851 | 0.030 |
Why?
|
| Profilins | 1 | 2015 | 66 | 0.030 |
Why?
|
| Immunosorbent Techniques | 1 | 1995 | 184 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2016 | 321 | 0.030 |
Why?
|
| Myoclonus | 1 | 1995 | 104 | 0.030 |
Why?
|
| Heterozygote | 1 | 2021 | 2790 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 17400 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2023 | 18006 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 683 | 0.030 |
Why?
|
| North America | 1 | 2017 | 1249 | 0.030 |
Why?
|
| Ocular Motility Disorders | 1 | 1995 | 135 | 0.030 |
Why?
|
| Femur Neck | 1 | 2015 | 309 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 4 | 2015 | 21821 | 0.030 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1995 | 150 | 0.030 |
Why?
|
| Phenotype | 2 | 2008 | 16331 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2011 | 789 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 628 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 975 | 0.030 |
Why?
|
| Cerebellar Diseases | 1 | 1995 | 222 | 0.030 |
Why?
|
| Craniotomy | 1 | 1997 | 729 | 0.030 |
Why?
|
| Nerve Fibers | 1 | 2016 | 688 | 0.030 |
Why?
|
| Receptors, Dopamine D4 | 1 | 2013 | 171 | 0.030 |
Why?
|
| Brain Edema | 1 | 1997 | 617 | 0.030 |
Why?
|
| Animals | 10 | 2023 | 168561 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2012 | 12164 | 0.030 |
Why?
|
| Massachusetts | 1 | 2005 | 8662 | 0.030 |
Why?
|
| Learning | 1 | 2001 | 1705 | 0.030 |
Why?
|
| Decompression, Surgical | 1 | 1997 | 593 | 0.030 |
Why?
|
| Mice | 6 | 2023 | 81045 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 1997 | 1007 | 0.030 |
Why?
|
| Proteome | 1 | 2022 | 1790 | 0.030 |
Why?
|
| Memory | 1 | 2001 | 2163 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2015 | 23387 | 0.030 |
Why?
|
| Founder Effect | 1 | 2012 | 190 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2023 | 8436 | 0.020 |
Why?
|
| Weight Loss | 1 | 2023 | 2604 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2008 | 8297 | 0.020 |
Why?
|
| Canada | 1 | 2016 | 2061 | 0.020 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2013 | 245 | 0.020 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2013 | 422 | 0.020 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2013 | 475 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 2271 | 0.020 |
Why?
|
| Calibration | 1 | 2013 | 815 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2015 | 688 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 508 | 0.020 |
Why?
|
| Energy Metabolism | 2 | 1999 | 2896 | 0.020 |
Why?
|
| International Cooperation | 1 | 2016 | 1421 | 0.020 |
Why?
|
| Organic Chemicals | 1 | 2010 | 211 | 0.020 |
Why?
|
| Venezuela | 1 | 2009 | 73 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 39004 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2015 | 1726 | 0.020 |
Why?
|
| Femur | 1 | 2015 | 1297 | 0.020 |
Why?
|
| Proteomics | 1 | 2022 | 3618 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2010 | 799 | 0.020 |
Why?
|
| Adolescent | 6 | 2020 | 85649 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2013 | 1539 | 0.020 |
Why?
|
| Child | 6 | 2020 | 77478 | 0.020 |
Why?
|
| Gene Expression | 2 | 2011 | 7790 | 0.020 |
Why?
|
| Penetrance | 1 | 2009 | 380 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 5180 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2012 | 933 | 0.020 |
Why?
|
| Cell Count | 1 | 2010 | 1831 | 0.020 |
Why?
|
| Macaca | 1 | 2008 | 440 | 0.020 |
Why?
|
| DNA | 2 | 2010 | 7289 | 0.020 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2008 | 191 | 0.020 |
Why?
|
| Research Design | 1 | 2022 | 5979 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2020 | 40955 | 0.020 |
Why?
|
| Zidovudine | 1 | 1988 | 620 | 0.020 |
Why?
|
| Cell Line | 2 | 2010 | 15994 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 3339 | 0.020 |
Why?
|
| Neocortex | 1 | 2009 | 400 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 2781 | 0.020 |
Why?
|
| Phenylbutyrates | 1 | 2005 | 69 | 0.020 |
Why?
|
| Plaque, Amyloid | 1 | 2008 | 729 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2013 | 2968 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1988 | 1791 | 0.010 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 2699 | 0.010 |
Why?
|
| Species Specificity | 1 | 2008 | 2479 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2011 | 13029 | 0.010 |
Why?
|
| Exons | 1 | 2009 | 2431 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2010 | 3001 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2013 | 4197 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2016 | 77098 | 0.010 |
Why?
|
| Probability | 1 | 2008 | 2502 | 0.010 |
Why?
|
| Bone Density | 1 | 2015 | 3469 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 12344 | 0.010 |
Why?
|
| Reference Values | 1 | 2009 | 4982 | 0.010 |
Why?
|
| Contrast Media | 1 | 2015 | 5295 | 0.010 |
Why?
|
| Embryonic Stem Cells | 1 | 2009 | 1294 | 0.010 |
Why?
|
| Radiography | 1 | 2013 | 7010 | 0.010 |
Why?
|
| Scopolamine | 1 | 2001 | 99 | 0.010 |
Why?
|
| Insulin | 1 | 2016 | 6575 | 0.010 |
Why?
|
| Muscarinic Antagonists | 1 | 2001 | 137 | 0.010 |
Why?
|
| Lorazepam | 1 | 2001 | 145 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2016 | 8541 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 2892 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 3770 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2009 | 6365 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2010 | 4143 | 0.010 |
Why?
|
| Mass Screening | 1 | 2015 | 5238 | 0.010 |
Why?
|
| Anti-Anxiety Agents | 1 | 2001 | 390 | 0.010 |
Why?
|
| Ecuador | 1 | 1998 | 55 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1988 | 6382 | 0.010 |
Why?
|
| Brain Diseases | 1 | 2008 | 1554 | 0.010 |
Why?
|
| Mutation | 2 | 2013 | 29717 | 0.010 |
Why?
|
| Ceramics | 1 | 1998 | 105 | 0.010 |
Why?
|
| Infant | 1 | 2020 | 35070 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1988 | 6483 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 7901 | 0.010 |
Why?
|
| Placebos | 1 | 2001 | 1677 | 0.010 |
Why?
|
| Age Factors | 1 | 2014 | 18355 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 12071 | 0.010 |
Why?
|
| Oxidative Phosphorylation | 1 | 1999 | 480 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 3920 | 0.010 |
Why?
|
| Industry | 1 | 1998 | 365 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 18112 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1988 | 10943 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 2006 | 2643 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 3800 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 4933 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 12797 | 0.010 |
Why?
|
| Lead | 1 | 1998 | 854 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 13403 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 12220 | 0.010 |
Why?
|
| Protons | 1 | 1998 | 1126 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 20086 | 0.010 |
Why?
|
| Genome, Human | 1 | 2005 | 4420 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 12958 | 0.010 |
Why?
|
| Neurons | 1 | 2009 | 9325 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 1997 | 1827 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 9410 | 0.010 |
Why?
|
| United States | 1 | 2016 | 69693 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 1998 | 1794 | 0.000 |
Why?
|
| Activities of Daily Living | 1 | 1997 | 2414 | 0.000 |
Why?
|
| Linear Models | 1 | 1998 | 5948 | 0.000 |
Why?
|
| Oxidative Stress | 1 | 1999 | 3081 | 0.000 |
Why?
|
| Cause of Death | 1 | 1997 | 3571 | 0.000 |
Why?
|
| Environmental Exposure | 1 | 1998 | 4231 | 0.000 |
Why?
|
| Survival Rate | 1 | 1997 | 12773 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1997 | 15244 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1997 | 53187 | 0.000 |
Why?
|